Small molecule Drugs

Leonurine Sulfate (SCM-198):

Derived from the natural product motherwort, representing a globally novel chemical entity with a new target and new mechanism of action!

Process Flow Chart
Motherwort
Active Ingredient
Leonurine
Synthetic Production
Pilot Scale

Global First-in-Class:

A first-in-class anti-cardiovascular inflammation drug targeting CD36, filling a global void in this therapeutic target area!

A first-in-class anti-cardiovascular inflammation drug targeting CD36, filling a global void in this therapeutic target area

Clinical studies demonstrate that leonurine sulfate (SCM-198) exhibits significant efficacy in treating chronic low-grade vascular inflammation

Clinical studies demonstrate that leonurine sulfate (SCM-198) exhibits significant efficacy in treating chronic low-grade vascular inflammation

Leonurine sulfate (SCM-198) is the first compound originating from China shown to be effective for non-alcoholic fatty liver disease

Leonurine sulfate (SCM-198) is the first compound originating from China shown to be effective for non-alcoholic fatty liver disease

Selected Indications Under Investigation

Hyperlipidemia Hyperlipidemia
Fatty Liver Non-Alcoholic
Fatty Liver Disease
Atherosclerosis Atherosclerosis
Endometriosis Endometriosis
Ulcerative Colitis Ulcerative
Colitis
Wound Healing Wound Healing

Leonurine Sulfate (SCM-198) Has Been
Sumitted For Dual China-US Regulatory Filings

China NMPA Clinical Trial Approval

National Medical Products Administration of China
Center for Drug Evaluation

Global
US FDA Response Letter

U.S. Food and Drug Administration

Intellectual Property

13 Granted Chinese Patents
1 Granted European Patent
with 1 application pending
1 Granted Japanese Patent
1 PCT International Patent

Substantial Commercial Value

150 Million RMB

Leonurine sulfate (SCM-198) achieved a successful technology transfer valued at RMB 150 million in 2016
——representing one of the few successful new drug commercialization cases in China

icon

>$200 Million USD

According to authoritative assessments, leonurine sulfate (SCM-198) is projected to achieve an overseas licensing valuation exceeding USD 200 million upon entering FDA Phase II clinical trials!

icon